Mumbai, April 9 -- Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.

"This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market," Concord Biotech said in a statement.

According to IQVIA, the market size of Teriflunomide tablets is approximately $402 million in the US, and the global market size is approximately $908 million, indicating significant opportunities for expansion in the US and the global market.

Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment.

The company's consolidated net profit ...